E
ChatBot cancel
smart_toy

Hello, I'm VAI. Are you new to Vease?

Example Image ChatBot cancel
Hello, I'm VAI. Are you new to Vease?

AI in Biotech

Digital representation of scientists using NVIDIA's BioNeMo for pharmaceutical research

NVIDIA’s BioNeMo: A New Era in Drug Discovery with AI

In the world of healthcare, something exciting is happening. NVIDIA is changing how we find new medicines. They’re using generative AI to make drug discovery faster and better.

Why NVIDIA’s Getting Noticed

  • Expertise in Tech: NVIDIA’s been busy building tools and expertise in digital biology. This means they’re ready to lead in using AI for healthcare.
  • Generative AI Tools: These tools can simulate drugs on a computer. This is huge because it lets scientists see how molecules work without always needing a lab.

The Star Player: BioNeMo Platform

  • What It Does: NVIDIA’s BioNeMo is like a super-tool for scientists. It helps create, tweak, and use AI models for finding new drugs.
  • Why It Matters: This platform can change how drugs are made. It can cut down on lab experiments, saving time and money.

The Big Benefits

  • Smarter Drug Design: BioNeMo lets researchers design molecules with the features they want. It’s like building the perfect Lego structure, but for medicine.
  • Fewer Experiments Needed: Less time in the lab means faster drug development. That’s good news for everyone waiting on new treatments.


Who’s Using It

Companies and researchers in biology, chemistry, and genomics are jumping on the BioNeMo bandwagon. It’s becoming a go-to tool in the science world.

Final Thoughts

NVIDIA’s BioNeMo is more than just tech talk. It’s a game-changer in making new medicines. Faster, smarter, and cost-effective – it’s what the future of drug discovery looks like. And that future is pretty exciting!

AI-driven biotech drug discovery

Alphabet’s AI-driven drug discovery Lab Isomorphic Lands Big Pharma Deals

Alphabet’s Isomorphic, an AI biotech startup, is making headlines with major pharmaceutical partnerships. Let’s dive into this exciting development in the AI and biotech world.

Isomorphic’s Big Pharma Breakthrough

Isomorphic has just inked deals with giants Eli Lilly and Novartis. The terms? An impressive $83 million upfront and potential milestone payments up to $2.9 billion. That’s huge!

Leveraging AlphaFold for Drug Discovery

Here’s where it gets interesting: Isomorphic uses Google DeepMind’s AlphaFold model. This is all about using AI to speed up drug discovery, a game-changer in pharmaceuticals.

Rapid Rise in AI Biotech

Since its start in November 2021, Isomorphic has been on a fast track. In less than a year, they’ve positioned themselves as key players in AI biotech.

Leadership and Growth

  • At the Helm: Demis Hassabis, CEO of Google DeepMind, is leading the charge. His expertise in AI is steering Isomorphic towards success.
  • Team and Locations: About 90 employees are fueling Isomorphic’s growth, based in London and Lausanne, Switzerland.

The Bottom Line

Isomorphic’s recent partnerships mark a significant milestone in AI-driven drug discovery. With its advanced use of AI and rapid growth, the company is set to revolutionize how we approach pharmaceuticals. Keep an eye on Isomorphic – they’re pushing boundaries in the exciting convergence of AI and biotech! πŸš€πŸ’ŠπŸ€–